Antisense drugs are small DNA – or RNA – drugs that are designed to target disease-associated proteins with the objective of slowing or stopping the progression of a disease. Ionis pharmaceuticals, in this new trial, is developing an investigational drug – IONIS GHR-LRx – that affects the underlying genetic cause of acromegaly and prevents the overproduction of insulin-like growth factor-1 (IGF-1). Their hope is that by reducing IGF-1, IONIS-GHR-LRx will be a viable monthly administered treatment option for patients with Acromegaly to help better control their disease. This study is designed to evaluate the safety and tolerability of an investigational compound, IONIS-GHR-LRx, in adult patients with acromegaly who are currently being treated with long-acting somatostatin receptor ligands and whose IGF-1 levels remain uncontrolled.
This study is designed to evaluate the safety and tolerability of an investigational compound, IONIS-GHR-L Rx, in adult patients with acromegaly who are currently being treated with long-acting somatostatin receptor ligands and whose IGF-1 levels remain uncontrolled.
There are currently three US sites that are open to recruitment. They are The University of Alabama Birmingham, Palm Research Center, Inc. in Las Vegas, Nevada, and St. Joseph’s Hospital and Medical Center in Phoenix, Arizona.
Talk to your physician to see if you fit the eligibility criteria.
To get more information and to learn more about the study and the eligibility criteria click here to download the brochure.
You can contact Ionis here patients@ionisph.com or visit www.clinicaltrials.gov
© 2019, Pituitary World News. All rights reserved.